PO16 - Hemorrhagic Complications in Patients with Hemophilia A

Background: Prophylactic administration of clotting factor FVIII with the frequency and doses determined by the averaged values provides a decrease in the number of hemorrhagic complications and the development of hemarthrosis

Aims: To evaluate the incidence of hemorrhagic episodes in hemophilia A patients with severe, moderate-to-severe course who are prescribed recombinant antihemophilic factor FVIII in the prophylactic regimen.

Methods: Prospective, randomized study. Thirty patients with hemophilia A and B over 18 years of age were included in the analysis. Patients in the first group (n = 15) received Oktofactor, and those in the second group (n = 15) received Advait. The first group included 13 patients with a severe form of hemophilia A (FVII activity less than 1%) and 2 patients with a moderate form of the disease (FVII activity 1-5%); the second group included 11 patients with a severe form of hemophilia A (FVII activity less than 1%) and 4 patients with a moderate form of the disease (FVII activity 1-4%).

Results: A prospective, randomized study
The follow-up period was 12 weeks. In the first group, 61 cases of hemorrhagic episodes were registered. Posttraumatic 15 (24,5%), spontaneous - 46 (75,4%). By severity: mild - 48 (78.6%) and 13 (21.3%) - moderate. In the second group there were 74 hemorrhagic episodes, 4 (5,4%) - mild, 69 (93,2%) - moderate and 1 (1,3%) - severe.
Posttraumatic - 21 (28.3%), spontaneous - 53 (71.6%). One case required hospitalization.

Conclusion(s): The vast majority - 36 (83.7%) hemorrhagic episodes were stopped by a single injection of Octofactor. For effective prevention of hemorrhagic complications, additional measures are required to increase adherence to therapy, including individualization of the prophylactic treatment regimen.